2 Cannabis Stocks That Could Land a Game-Changing Partner in 2020

Find out why stocks like HEXO Corp (TSX:HEXO)(NYSE:HEXO) and Green Organic Dutchman Holdings Ltd (TSX:TGOD) could be in for a transformational 2020.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Last year, nearly every cannabis company was racing to find a big-time partner. Cronos Group, for example, secured a $1.8 billion deal with tobacco giant Altria Group. Cronos stock ran more than 100% on the news, rising to a peak market cap of $20 billion. Canopy Growth, meanwhile, locked down a $4 billion capital infusion from Constellation Brands, causing shares to skyrocket.

While the initial rush for partners sent cannabis stocks into the stratosphere, the back half of 2019 has been much quieter. In fact, many pot ETFs are down 50% or more in value. While this has created pain for marijuana investors, it’s also created opportunity for new partners to enter the space at attractive price points. In 2020, I expect a number of pot stocks to secure game-changing partnerships that could resurrect their struggling share prices.

Whichever companies attract the best partners will likely lead the industry in gains. The best time to place your bets is today. Here are two undervalued pot stocks ripe for a transformational partner.

Play the platform

Canopy Growth and Cronos shared one big characteristic before securing valuable partners: an early lead. In the ever-evolving world of pot, Altria and Constellation chose to invest in companies that had a head start on production, marketing, and distribution. If you want to bet on what’s worked thus far, HEXO (TSX:HEXO)(NYSE:HEXO) is the way to go.

HEXO is attempting to build the first platform for the cannabis industry. It has a grow facility in Quebec capable of producing more than 100,000 kilograms of pot per year, a truly massive 580,000-square-foot processing and R&D centre in Ontario, and a 58,000-square-foot distribution facility in Montreal.

In a nutshell, HEXO wants to create a platform so that any company in the world can use its services to create, manufacture, and sell cannabis products quickly and efficiently. It’s this positioning that makes HEXO the ideal buyout candidate. Over the next 12 months, HEXO will be a plug-and-play partner for any company looking to enter the space in a meaningful way. It’s already demonstrated early success. In 2018, it partnered with Molson Coors Canada to help create cannabis-infused beverages.

While HEXO is well positioned to attract more one-off partners, it shouldn’t be ignored that it has essentially built a vertically integrated cannabis company that can integrate seamlessly with a large acquirer like Coca-Cola or Kraft Heinz. If a multi-billion-dollar company wants to make a splash, HEXO is the most obvious target.

The ground floor

If you want to take a bit more risk, Green Organic Dutchman Holdings (YSX:TGOD) is the way to go. Its market cap is 60% smaller than HEXO, and the upside is commensurately higher. Green Organic recently lost its key partner, Aurora Cannabis, and is primed for a new partner to swoop in. The company has two major facilities ramping production next quarter, and all that pot needs somewhere to go.

In reality, Green Organic isn’t as well positioned as HEXO. It doesn’t have the ancillary infrastructure in place and is positioned closer to a pure-play grower. While an outside company likely won’t be interested, there’s big potential for interest from inside the industry. Aurora didn’t need Green Organic’s cannabis output because its internally owned Whistler Medical was already supplying it with enough output. If any pot company experiences disruptions in its supply chain, Green Organic will be at the top of its list.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of Molson Coors Brewing. Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »